Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

602
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
602
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

2.3K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arterial and venous thromboembolism in hospitalized patients with COVID-19: a national multicenter cohort study.

Blood vessels, thrombosis & hemostasis·2026
Same author

Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial.

Clinical kidney journal·2026
Same author

Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19.

Critical care explorations·2026
Same author

Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II.

JACC. Heart failure·2026
Same author

Incidence and clinical outcomes of extended duration support in patients with Impella 5.5 - Analysis from the LOQI Registry.

JHLT open·2026
Same author

Safety and Feasibility of IVC Flow Modulation With the Doraya in Acute Decompensated Heart Failure.

JACC. Heart failure·2026

Related Experiment Video

Updated: May 4, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K

Fluid Management of Acute Heart Failure With the Reprieve System: The Randomized Controlled FASTR Trial.

James E Udelson1, Ali Javaheri2, Marat Fudim3

  • 1Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.

JACC. Heart Failure
|May 2, 2026
PubMed
Summary

The Reprieve System safely and rapidly decongested acute heart failure patients in a pilot trial. This automated system demonstrated superior natriuresis and faster fluid loss compared to standard care.

Keywords:
acute heart failurediuresisdiureticheart failurenatriuresisurine sodium

More Related Videos

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

10.9K

Related Experiment Videos

Last Updated: May 4, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.1K
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
07:59

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol

Published on: July 28, 2018

10.9K

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Devices

Background:

  • Barriers to safe and rapid decongestion in acute heart failure necessitate innovative solutions.
  • The Reprieve System offers automated diuretic titration and real-time monitoring to prevent cardio-renal dysfunction.
  • Individualized sodium chloride replacement is a key component of the Reprieve System's strategy.

Purpose of the Study:

  • To establish proof-of-concept for the Reprieve System's ability to facilitate rapid and safe decongestion.
  • To compare the efficacy and safety of the Reprieve System against optimal diuretic therapy (ODT).

Main Methods:

  • The FASTR trial was a randomized pilot study involving hospitalized acute heart failure patients.
  • Patients were randomized to either the Reprieve System or a control strategy of ODT.
  • Primary endpoints included 24-hour natriuresis (efficacy) and a composite safety endpoint (dialysis, creatinine doubling, etc.).

Main Results:

  • The Reprieve System group showed significantly greater 24-hour natriuresis (1082 ± 487 mmol) compared to ODT (423 ± 290 mmol; P < 0.001).
  • Faster rates of weight loss (P = 0.002), net fluid loss (P = 0.03), and net natriuresis (P < 0.001) were observed with Reprieve.
  • The safety endpoint occurred in 31% of the Reprieve group vs. 39% of the ODT group (P = 0.42), with shorter diuretic therapy duration for Reprieve.

Conclusions:

  • The Reprieve System demonstrated safe and significantly faster decongestion compared to ODT in this pilot trial.
  • Further confirmation is required in the ongoing pivotal trial to validate these promising findings.
  • The Reprieve System (NCT05174312) shows potential for improving acute heart failure management.